Evidence that the androgen receptor (AR) is not only important in androgen-dependent prostate cancer, but also continues to play a role in tumors that become resistant to androgen deprivation therapies, highlights the need to find alternate means to block AR activity. AR, a hormone-activated transcription factor, and its coactivators are phosphoproteins. Thus, we sought to determine whether inhibition of specific cell signaling pathways would reduce AR function. We found that short-term inhibition of p42/p44 MAPK activity either by a MAPK kinase inhibitor, U0126, or by depletion of kinase with small interfering RNA caused target gene-specific reductions in AR activity. (1) have found that a very high percent of prostate tumors contain a somatic genetic rearrangement, which results in a fusion between the promoter region of the androgen-regulated TMPRSS2 gene and the coding region of an Ets factor. Thus, the expression of this fusion is dependent on AR action. There is increasing evidence that recurrent prostate tumors remain AR dependent. In comparisons of androgendependent tumors with androgen-independent tumors from humans and from xenografts, the most consistent difference is an elevation in AR expression in the androgen ablation-resistant tumors (2). Moreover, the recurrent tumors reexpress many AR-regulated targets including prostate-specific antigen (PSA). Eliminating AR expression or activity in AR-positive androgen-independent prostate cancer cells blocks cell proliferation and eliminates PSA expression (3, 4), supporting the concept that tumors develop alternate means for activating AR in the absence of normal levels of androgens. Consequently, understanding the aberrant activation of AR and developing means to inhibit its activity are high priorities. A number of potential mechanisms for reactivation of AR have been proposed, including increased AR expression, altered steroid metabolism resulting in elevated levels of androgens in tumors, and altered cell signaling that results in the activation of AR in the absence of normal levels of androgens (5). Several studies have implicated HER2 signaling in regulating AR protein stability, sensitizing AR to low levels of androgens, and even in inducing hormone-independent activation (6, 7). Typical of most growth factor signaling, multiple signaling pathways are activated by HER2 heterodimers. The downstream kinase(s) responsible for regulating AR
A LTHOUGH THE IMPORTANCE of the androgen receptor (AR) and androgens in prostate cancer has long been recognized, several recent findings underscore the contribution of AR in primary tumors and in recurrent cancers subsequent to androgen ablation. Tomlins et al. (1) have found that a very high percent of prostate tumors contain a somatic genetic rearrangement, which results in a fusion between the promoter region of the androgen-regulated TMPRSS2 gene and the coding region of an Ets factor. Thus, the expression of this fusion is dependent on AR action. There is increasing evidence that recurrent prostate tumors remain AR dependent. In comparisons of androgendependent tumors with androgen-independent tumors from humans and from xenografts, the most consistent difference is an elevation in AR expression in the androgen ablation-resistant tumors (2) . Moreover, the recurrent tumors reexpress many AR-regulated targets including prostate-specific antigen (PSA). Eliminating AR expression or activity in AR-positive androgen-independent prostate cancer cells blocks cell proliferation and eliminates PSA expression (3, 4) , supporting the concept that tumors develop alternate means for activating AR in the absence of normal levels of androgens. Consequently, understanding the aberrant activation of AR and developing means to inhibit its activity are high priorities. A number of potential mechanisms for reactivation of AR have been proposed, including increased AR expression, altered steroid metabolism resulting in elevated levels of androgens in tumors, and altered cell signaling that results in the activation of AR in the absence of normal levels of androgens (5) . Several studies have implicated HER2 signaling in regulating AR protein stability, sensitizing AR to low levels of androgens, and even in inducing hormone-independent activation (6, 7) . Typical of most growth factor signaling, multiple signaling pathways are activated by HER2 heterodimers. The downstream kinase(s) responsible for regulating AR expression and activity have not been identified although Akt has been eliminated as a candidate (7) . Other studies show that AR protein is more stable in androgen-independent than in androgen-dependent cell lines and that the androgen-independent cells are hypersensitive to low levels of androgens (8) . The hypersensitivity to androgens can be induced by expressing a Ras effector mutant that selectively activates Raf, leading to activation of p42/p44 MAPK (also called ERK1/ERK2) (9) . Interestingly, elevated p42/p44 MAPK signaling has been detected in advanced prostate tumors (10) . Our studies show that blocking p42/ p44 MAPK activity recapitulates the observed reductions in PSA expression and AR stability caused by inhibition of HER2 (7) . Studies to date have relied on measuring AR activity using AR-responsive reporters or endogenous PSA. However, we find that inhibition of p42/p44 MAPK reduces AR activity in a target gene- A, LNCaP cells were preincubated for 24 h in medium supplemented with 10% charcoal stripped serum (sFBS), 1 nM R1881, and vehicle (DMSO) or 20 M UO126 was added to the medium and cells incubated for 12 h; except 100 ng/ml of EGF was added where indicated only for the last 10 min. Cells were harvested and AR, phospho-ERK1/2, and actin expression was measured by Western blotting. B-E, LNCaP cells were treated with the indicated amount of R1881 and either DMSO as a vehicle or 20 M UO126 for 12 h. Total RNA was prepared as described in Materials and Methods and analyzed for PSA (B), TMPRSS2 (C), PMEPA1 (D), and PCDH11 (E) expression by quantitative RT-PCR. All expression values were normalized to 18S RNA expression, each point was done in triplicate, and mean and SD were calculated. The experiments were repeated three times, and a representative experiment is shown. v, Vehicle. specific manner. Using mammalian two-hybrid assays, we found that kinase inhibition reduces AR amino-carboxyl terminal interactions as well as the interaction between AR and the p160 coactivator, steroid receptor coactivator (SRC)-1. Consistent with this, we found that target genes that exhibit increased histone H3 acetylation in response to androgen are sensitive to the MEK inhibitor, whereas those with no hormone-dependent increase in histone H3 acetylation are resistant. Long-term inhibition of MEK activity causes a G 1 arrest and reduces AR stability. Thus, treatments that reduce p42/p44 MAPK activity in prostate cancer have the potential to reduce AR activity through a reduction in expression levels as well as by target gene-selective inhibition of AR function.
RESULTS

Inhibition of MEK Reduces AR Transcriptional Activity in a Promoter-Specific Manner
To examine the impact of MAPK signaling on AR transcriptional activity, we treated LNCaP cells with U0126, a MEK inhibitor that blocks activation of p42/ p44 MAPK. At 12 h the level of AR in LNCaP treated with the synthetic androgen, R1881, was unchanged by U0126 treatment whereas phosphorylation of MAPK was inhibited (Fig. 1A) . Induction of two wellknown AR target genes, PSA and TMPRSS2, was reduced ( Fig. 1, B and C) . In contrast, another ARactivated target gene PMEPA1 (11, 12) and an ARrepressed gene PCDH11 (13) were insensitive to MAPK inhibition at the 12-h time point (Fig. 1, D and E) . Thus, the requirement for p42/p44 MAPK signaling is target gene dependent.
ERK1 and ERK2 Differentially Contribute to AR Activity
MAPK kinase (MEK) inhibition prevents the direct activation of two kinases, ERK2 (MAPK1/p42) and ERK1 (MAPK3/p44), which are both expressed in LNCaP cells (14) . To eliminate the possibility of off-target effects of U0126 and to determine whether there is downstream kinase specificity, we reduced expression of each of these kinases separately using small interfering RNA (siRNA). As shown in Fig. 2 , A and B, ERK1 and ERK2 expression and protein levels were effectively reduced by their respective siRNAs, and there was no androgen dependence of kinase mRNA or protein expression (Fig. 2, A and B) . Consistent with the effect of UO126 on AR target gene expression, PMEPA1 expression was not affected by a reduction in either kinase (Fig. 2C) . PSA expression was sensitive to the reduction in ERK2 only (Fig. 2D) , whereas TMPRSS2 required both ERK1 and ERK2 (Fig. 2E) for optimal expression. The proliferation of LNCaP cells, measured using [ 3 H]thymidine incorporation, was inhibited by reducing either ERK1 or ERK2; however, ERK2 seems to have a more profound effect on proliferation (Fig. 2F ).
U0126 Treatment Reduces AR Protein Interactions
Because both SRC-1 and AR are phosphoproteins and SRC-1 is a direct target of MAPK (15), we used mammalian two-hybrid assays to measure effects of MEK inhibition on AR protein-protein interactions, including the AR amino/carboxyl (N-C) terminal and AR SRC-1 interactions, which are required for optimal induction of many target genes (16) . Using a plasmid expressing the AR amino terminus and DNA binding domain linked to the VP16 activation domain and a plasmid expressing the AR DNA binding domain and hormone binding domain linked to a Gal-DNA binding domain, we observed a significant reduction in interaction of the two receptor fragments in the presence of UO126 (Fig. 3A, left) . In contrast, the activity of a constitutively active VP16 activation domain linked to a Gal-DNA binding domain was unaffected by treatment (Fig. 3A, right) , indicating that it is the interaction between the portions of the AR that is reduced.
SRC-1 is a histone acetyltransferase (HAT) and recruits other HATs to the promoters. In addition, MAPK-dependent phosphorylation of the p160 coactivator, SRC-1, has been shown to be necessary for IL-6 dependent potentiation of AR activity (17) . To determine whether U0126 reduced interaction between SRC-1 and AR, we used a mammalian twohybrid assay and found that U0126 greatly decreased the interaction between AR and SRC-1 (Fig. 3B) . Note that the interaction is hormone independent; the major SRC-1 interaction site on AR is the hormone-independent activation function 1 (AF-1) rather than the hormone binding domain (18) . Because Gioeli et al. (19, 20) have reported that AR is not phosphorylated by ERK1/2, we sought to determine whether MAPK signaling directly affects SRC-1 phosphorylation by examining the level of phosphorylation on Thr1179 and Ser1185 of flag-tagged SRC-1 expressed in COS-1 cells. Overnight treatment with UO126 did not alter the level of SRC-1 (input protein in Fig. 3C ) or the amounts of immunoprecipitated flag-tagged SRC-1 (IP and WB with total SRC-1 specific antibodies, lanes 4 and 6, Fig. 3C ). In contrast, treatment with U0126 essentially eliminated phosphorylation of Thr 1179 and Ser 1185 (Fig.  3D) , suggesting that SRC-1 is a direct target of MAPK signaling. Because androgen-dependent repression of PCDH11 is resistant to MEK inhibition, we asked whether SRC-1 is required for androgen-dependent repression. Depletion of SRC-1 using siRNA did not alter the ability of AR to repress PCDH11 (Fig. 3E ).
U0126 Treatment Reduces the Rate of AR Recruitment to Target Gene Binding Sites
To elucidate the effects of U0126 on AR activity, R1881-dependent recruitment of AR to the PSA, TM-PRSS2, and PMEPA1 target genes was measured. As shown in Fig. 4 , inhibition of MEK in LNCaP cells significantly reduced recruitment of AR to the PSA promoter and enhancer (Fig. 4A) , TMPRSS2 promoter and enhancer (Fig. 4B) , and PMEPA1 enhancer ( fact that there are similar amounts of AR under both conditions (Fig. 4D) . After 16 h of treatment, U0126 no longer has an effect on AR binding (Fig. 4 , A-C).
Inhibition of MEK Reduces Androgen-Dependent Acetylation of Histone H3 at the PSA and TMPRSS2 Promoters and Enhancers
Activated AR recruits a series of HATs including the p160 family members and p300 to the PSA promoter and enhancer resulting in increased acetylation of histone H3 (21) . To determine whether MEK inhibition reduces HAT activity at AR target genes, we examined the levels of acetyl H3 histone on the androgen-regulated promoters. Intriguingly, the level of acetylation of H3 on the promoters and enhancers of UO126-sensitive genes, PSA and TMPRSS2, increased with androgen treatment, and this increase was compromised by MEK inhibition (Fig. 5, A and B) . Acetylation levels of H3 histone at the promoter and enhancer of PMEPA1 
Fig. 3. MAPK Signaling Affects Inter-and Intramolecular AR Interactions
A, PC-3 cells were transfected with 400 ng 17mer-Luc, and the indicated combinations of 100 ng of pBind (Promega) or pBind-AR-NTD, 100 ng of pAct (Promega) or pAct-AR-DH as described in Materials and Methods. Cells were treated with either vehicle or 10 nM R1881 with or without 20 M U0126 overnight and assayed for luciferase activity, which was then normalized for the level of total protein. On the right, PC-3 cells were transfected with 400 ng of 17mer-Luc reporter and 10 ng of pBind-VP16 expression plasmid. Cells were then treated with either DMSO or 20 M UO126 overnight, harvested, and assayed for luciferase activity and total protein. B, PC-3 cells were transfected with 400 ng 17mer-Luc, the indicated combinations of 100 ng of pBind or pBind-SRC-1a, and 100 ng of pAct or pAct-AR. Cells were treated overnight with either vehicle (empty bars) or 10 nM R1881 (solid bars), and either DMSO or 20 M UO126 as indicated. Cells were harvested and assayed for luciferase activity and protein concentration. In experiments A and B, each point was done in triplicate, the experiments were repeated three times, and a representative experiment is shown. C and D, COS1 cells were transfected with flag-SRC-1 expression plasmid. After 24 h cells were treated with either DMSO or 20 M UO126 for 12 h and harvested, and protein was extracted in the presence of protease and phosphatase inhibitors. Protein from each treatment group (1.5 mg) was used for immunoprecipitation (IP) with SRC-1-specific antibody. In panel C, lanes 1 and 2 are 50 g of the input protein extract treated with either DMSO or 20 M UO126; lanes 3-6 are 10% of immunoprecipitated material from cells treated with DMSO (lanes 3-4) or UO126 (lanes 5-6), using beads alone (lanes 3 and 5) or with flag antibody (lanes 4 and 6) were resolved on 6.5% PAGE and analyzed by Western blotting with total SRC-1 antibody. In D, 40% of the immunoprecipitated material was resolved on two separate 6.5% gels and analyzed by Western blotting using either pThr1179 or pSer1185 phospho-specific antibody. E, LNCaP cells were electroporated with either control or SRC-1 siRNA and plated in medium supplemented with 10% sFBS. Cells were treated 24 h later with either control or 1 nM R1881 for another 24 h. RNA was isolated and analyzed for 18S, PCDH11, and SRC-1 expression. Expression in the cells transfected with control (C) siRNA and treated with vehicle was designated as 100%, and all other values were adjusted proportionally. Each point was done in triplicate, and the experiment was repeated three times. Ab, Antibody; Act, actin; Bind, binding; RLU, relative light units; WB, Western blotting.
were unchanged either by androgen treatment or MEK inhibition (Fig. 5C ). This suggests distinct target genespecific roles for AR. Because AR was not required to increase acetylation of histone H3 upstream of PMEPA1 gene, we speculated that it might be primed for initiation. Thus, we tested whether genes that require histone acetylation at the promoter and enhancer are induced more slowly by androgens compared with PMEPA1, which does not require this additional step for transcriptional activation. We found that, indeed, PMEPA1 expression was induced more rapidly than PSA expression (Fig. 5D ). TMPRSS2 was induced more slowly than PMEPA1 as well (data not shown).
Inhibition of MAPK Reduces AR Stability
In examining AR expression in androgen-dependent LNCaP cells and in androgen independent C4-2 cells, we noted that AR expression was similar in fetal bovine serum (FBS), but that AR expression in LNCaP cells decreased upon transfer to medium containing charcoal-stripped serum (which is depleted of steroids and small hydrophobic peptides), whereas AR levels in C4-2 cells are maintained (Fig. 6A) . The C4-2 cell line is an androgen-independent derivative of the LNCaP cell line (22) that expresses AR and a subset of its target genes in medium depleted of androgens; under these conditions, proliferation and PSA expression remain AR dependent (4) . Others have shown that inhibition of HER2 signaling reduces AR stability through an Akt-independent mechanism (7). To test whether p42/p44 MAPK regulates AR expression, LNCaP and C4-2 cells were treated with 20 M U0126. Remarkably, 48 h of treatment had a profound effect on the levels of AR protein in both LNCaP (Fig. 6B ) and C4-2 ( Fig. 6C ) cells, with a modest reduction in AR mRNA (Fig. 6 , B and C, lower) suggesting posttranscriptional regulation. As expected for an AR-dependent gene, PSA expression was also strongly inhibited (Fig. 6 , B and C). To determine whether the decrease in AR protein was caused by increased protein turnover, C4-2 cells were treated with cycloheximide in the absence or presence of U0126, and AR expression was determined by Western blotting. As shown in Fig. 6D , AR protein was much less stable in the presence of U0126. Moreover, treating with the proteasome inhibitor, MG132, largely counteracted the effects of U0126 on AR expression in LNCaP and C4-2 cells (Fig. 6, E and F) , suggesting that proteasome-mediated degradation of AR was enhanced by U0126 treatment. 
MAPK Activity Is Necessary for Optimal LNCaP and C4-2 Cell Growth
Both the androgen-dependent LNCaP and the androgen-independent C4-2 cells require AR for proliferation (3, 4) . We have shown that ablation of either ERK1 or ERK2 using siRNA led to decreased proliferation of the LNCaP cells (Fig. 2F) . To assess the effect of MEK inhibition on LNCaP and C4-2 cell proliferation, cells were treated with UO126 and (Fig. 7B) . Consistent with previous reports, the LNCaP cells didn't grow significantly in charcoal-stripped FBS (sFBS) (Fig. 7B) (Fig. 7C) , almost eliminated any increase in cell number in FBS, and eliminated growth in sFBS (Fig. 7D) . To determine whether the MAPK dependence of cell growth in prostate cancer cells is AR dependent, we treated AR-negative PC-3 cells with either dimethylsulfoxide (DMSO) or UO126. PC-3 proliferation was reduced by U0126 treatment (Fig. 7E) , demonstrating that growth regulation by MAPK signaling also has an AR-independent component. The decrease in proliferation of the UO126-treated cells was due to an accumulation of cells in G 1 /G 0 phase (Fig.  7F ) that was most evident after 48 h of treatment.
Chen et al. (24) have reported that AR stability is regulated by cyclin-dependent kinase (CDK)1. Typically, CDK activity is limited by the levels of activating partner cyclins. In agreement with the change in cell cycle distribution, expression of the CDK1 partners, cyclin B and cyclin A2, was decreased in UO126-treated cells compared with those treated with vehicle (Fig. 7G) . Because U0126 treatment causes reductions in AR protein only after prolonged treatment, we suggest that this reduction may be a consequence of the reduction in CDK1 activity. ChIP was performed using antiacetyl H3 antibody (Millipore) as described in Materials and Methods. Immunoprecipitated DNA was analyzed for PSA promoter and enhancer sequences (A), TMPRSS2 promoter and enhancer (B), and PMEPA1 enhancer and immediate promoter sequences (C). In panels A-C, each point was done in duplicate, experiments were repeated three times, and fold induction was averaged. D, LNCaP cells were incubated for 36 h in 10% sFBS and treated with 1 nM R1881 for the indicated lengths of time. Cells were harvested and analyzed for PSA, PMEPA1, and 18S expression. Maximal expression during 16 h was assigned as 100%, and other values were proportionally adjusted. Each point was done in triplicate and average and SE was calculated. The experiment was repeated three times and a representative experiment is shown.
DISCUSSION
The importance of AR in prostate cancer and the frequent failure of androgen deprivation therapies have led to efforts to identify alternate means for inhibiting AR activity. Indeed, primary tumors, recurrence, and failure of androgen blockade are frequently detected by rising levels of serum PSA, an androgen-regulated gene. Although AR action is growth stimulatory in the epithelial prostate cancer cells, in normal prostate epithelial cells it participates in production of tissuespecific secreted proteins. It is the stromal cell AR that is needed for development of the prostate and growth of the epithelial cells (25) . Selective elimination of AR in mouse prostate epithelial cells increases proliferation (26) . The activities of AR in prostate cancer cells are a combination of acquired autocrine growth-stimulatory actions and activities of normal prostate epithelial cells including the induction of secreted proteins such as the kallikreins and regulation of genes to limit proliferation. For example, AR action inhibits the production of PCDH11, an activator of Wnt signaling (13) that stimulates proliferation and is up-regulated in advanced prostate cancer (27) . Moreover, we have shown that androgens repress expression of transcriptional intermediary factor (TIF)2, a p160 coactivator important both for ARdependent and AR-independent cell growth (28). Thus, some AR actions are beneficial, and a way to selectively inhibit AR actions potentially is more useful than elimination of all AR activity.
In contrast to most steroid receptors the transcriptional activities of which are strongly dependent on the activation function in the hormone binding domain (AF-2), the amino-terminal AF-1 is dominant in AR (18) . Antagonists, which bind the hormone binding domain, are less effective in blocking AF-1 function. The AR and its coactivators are phosphoproteins; consequently, inhibition of specific kinases is a potential alternative or addition to use of an antagonist for inhibiting AR action. Many of the known phosphorylation sites in AR and in the coactivators contain Ser/Thr-Pro motifs, which are often substrates of mitogen-activated kinases or of cyclin-dependent kinases. Elevated p42/p44 MAPK activity presumably due to elevated growth factor receptor signaling has been reported in more advanced prostate cancers (10) , and the p160 family of coactivators are all targets of these kinases (15, (29) (30) (31) . Inhibition of AR-responsive reporter activity and/or PSA expression by a MEK inhibitor has been reported previously (23, 30) . We sought to examine the effects of p42/p44 MAPK on the ability of endogenous AR to regulate endogenous target genes and found that the change in induction or repression was target gene specific. Treatment with U0126 for 12 h decreased hormone-dependent induction of PSA and TMPRSS2. However, expression of another primary AR target gene PMEPA1 and the ARrepressed gene PCDH11 was unchanged. To confirm these findings and to eliminate potential off-target ef- fects of U0126, we reduced expression of ERK1 (p42) and ERK2 (p44) separately using siRNA. Expression of ERK1 alone was sufficient for optimal PSA expression, and neither kinase affected PMEPA1 expression similar to the effects of U0126. These experiments were particularly important because Gioeli et al. (20) found that stress-activated kinases reduced AR activity but that reducing expression of MEK1/MEK2, the upstream activators of ERKs, had no effect on induction of PSA. This suggested that U0126 might have some off-target effects or that there is a MEK1/MEK2 independent means to activate ERKs. However, we find that direct elimination of ERKs substantially alters AR activity and the gene-specific pattern mimics the effects of U0126.
The gene-specific effects on AR action have both clinical and mechanistic implications. Interestingly, we found that TMPRSS2 expression was sensitive to loss of either ERK2 or ERK1; this androgen-regulated promoter is linked to portions of the coding region of an Ets factor in more than 60% of prostate cancers (1), and these studies suggest that MEK inhibitors would substantially reduce expression of these gene fusions. On the other hand, our studies highlight the problem in using PSA as a proxy for AR activity. PSA is a protease normally secreted into the lumen of the prostate, but found in the serum of prostate cancer patients; the PSA level in blood is a convenient surrogate measure of prostate tumor burden. Measuring PSA levels in AR-positive prostate cancer cell lines is typically used to evaluate overall AR activity. However, our studies show that measuring PSA induction is not an accurate reflection of all AR activities. Consistent with this, Sathya et al. (32) have shown that some synthetic AR ligands that are selective AR modulators can induce prostate cancer cell growth without inducing PSA.
The target gene-specific differences in requirements for ERK1/ERK2 likely reflect different cofactor requirements for target gene regulation. U0126 treatment reduced recruitment of AR to PSA and TMPRSS2 promoters and enhancers and to the PMEPA1 promoter after a 1-h treatment with R1881, but this deficiency is overcome at later times. Genes, the regulation of which is sensitive to MEK inhibition, exhibited androgen-dependent increases in acetylation of histone H3, which changes chromatin structure making the DNA more accessible to transcription factors. This acetylation was partially inhibited by U0126 treatment. In contrast, androgen does not induce histone H3 acetylation of the MEK inhibitor-resistant gene, PMEPA1. Presumably, the histones at this locus are adequately acetylated, and AR is only needed either to recruit other coactivators or to recruit factors such as cyclin T/Cdk9, which phosphorylate Pol II-promoting transcriptional elongation. Interactions between cyclin T/Cdk9 (P-TEFb) and AR have been reported previously (33) . Consistent with the idea that PMEPA1 requires fewer steps before induction of mRNA synthesis, the expression of PSA lags behind induction of PMEPA1 in a time course of androgen-dependent induction. To date, there is no evidence that AR is a direct target of the ERKs (19, 20) , but new studies reveal that androgen-dependent induction of subsets of target genes requires collaborating transcription factors and, in the case of PSA and TMPRSS2, GATA2 is required not only for optimal androgen-dependent induction, but also for optimal AR binding to the enhancers of these two target genes (34) . Phosphorylation of GATA-2 by ERKs has been described although the sites and function have not been elucidated (35) . In addition, the p160 coactivators are targets of ERK signaling. We have shown previously that both SRC-1 and TIF2 are required for optimal induction of PSA and TMPRSS2 (4, 28) . We found that MEK inhibition reduced the interaction between SRC-1 and AR in a mammalian two-hybrid assay and eliminated phosphorylation of Thr 1179 and Ser 1185 in SRC-1; these sites are important for functional cooperation between SRC-1 and CBP (36) . Gregory et al. (30) found that epidermal growth factor (EGF) treatment enhanced interaction between the AR ligand binding domain and TIF2 in a mammalian two-hybrid assay. Moreover, mutation of a MAPK consensus phosphorylation site in TIF2, Ser(736), reduced this interaction (30) . Our finding that the genes that undergo hormone-dependent acetylation are sensitive to MEK inhibition is consistent with concept that MEK inhibition reduces AR interaction with HATs. Although coactivators can also facilitate transcriptional repression, the requirement for specific coactivators is target gene specific. We found that SRC-1, but not TIF2, was required for ARdependent maspin repression (4, 28) . In the case of PCDH11, we found that eliminating SRC-1 had no effect on the ability of AR to repress its expression.
In addition to the changes in the intrinsic activity of AR, we also found that longer term inhibition of MEK with UO126 led to reduced levels of AR protein with minimal changes in AR mRNA levels. The interactions between the amino and carboxyl termini of AR have been implicated in stabilization of the receptor (37) . Overexpression of TIF2/glucocorticoid receptor interacting protein 1 increases expression of an AR mutant lacking the N/C interaction motifs either in the presence of dihydrotestosterone or EGF (30) . Thus, both N/C interactions and coactivator interactions can contribute to the overall stability/expression of the protein and both are sensitive to MEK inhibition. The reduction in the N/C terminal interaction in a two-hybrid assay despite the apparent lack of MAPK phosphorylation of AR suggests that proteins such as SRC-1 and TIF2, which interact with regions in the N terminus as well as the ligand-binding domain, serve as bridges between the two regions. A recent study implicates CDK1 in stabilization of AR (24) . The prolonged treatment with U0126 caused a G 1 arrest and corresponding reduction in the cyclins that partner with CDK1. Thus, the reduction in CDK1 activity also should result in decreased AR stability.
Previous reports have shown that AR is more stable in androgen-independent prostate cancer cells (8) , and our study shows that transfer of LNCaP and C4-2 cells to medium containing charcoal-stripped serum depleted of steroids and small hydrophobic growth factors leads to a reduction in AR protein in androgendependent LNCaP cells, but not in androgen-independent C4-2 cells. U0126 treatment of C4-2 cells substantially decreases AR stability, suggesting that enhanced autocrine growth factor signaling and continued progression through the cell cycle contributes to maintenance of AR expression facilitating AR activity in androgen-depeleted medium. In tumors, the combination of enhanced p160 coactivator expression (4, 28, 38, 39) and elevated cell signaling likely contributes to increased AR levels and facilitates AR action despite a reduction in androgens. Thus, inhibition of MAPK signaling is a candidate for inhibition of AR activity and expression in androgen-independent cancers. 
MATERIALS AND METHODS
Materials
Cell Culture
LNCaP, PC-3, and COS-1 cells were obtained from American Type Culture Collection (ATCC, Manassas, VA). C4-2 cells were purchased from UroCor, Inc. (Oklahoma City, OK). Cells were maintained in RPMI 1640 with 10% FBS (Intergen Co., Purchase, NY) (LNCaP), DMEM/F12 with 5% FBS (PC-3), T medium with 5% FBS (C4-2), and DMEM with 5% FBS (COS-1) with penicillin and streptomycin (Invitrogen, Carlsbad, CA). All cell lines were maintained at 37 C in a humid atmosphere containing 5% CO 2 . Tissue culture supplies were purchased from Fisher Scientific (Pittsburgh, PA). All chemicals were reagent grade unless otherwise indicated.
Plasmids
Expression plasmids pAct and pBind were purchased from Promega. Expression plasmids pAct-AR (full-length AR), pAct-ARDH (AR DNA and hormone-binding domains), pBind-AR-NTD (AR amino terminus and DNA-binding domain) [kindly provided by Dr. Elizabeth Wilson, University of North Carolina, Chapel Hill, NC (37, 40) ], pCR3.1-AR, pBind-SRC-1, GRE2E1b-luciferase [an AR-responsive reporter provided by Dr. Carolyn Smith (Baylor College of Medicine, Houston, TX], and 17mer-luc were described previously (41) . Expression plasmid pSVL-flag-SRC1 was kindly provided by Dr. David Moore (Baylor College of Medicine).
Transfection, Luciferase, ␤-Galactosidase, and Proliferation
Assays were performed as were previously described (4, 41) . Plasmid transfections were performed using polylysine-coupled adenovirus. The luciferase assay was performed using a Promega kit. 2-Nitrophenyl ␤-D-galactopyranoside (Sigma) colorimetric assay was used to determine ␤-galactosidase activity.
As a surrogate for proliferation, we measured the incorporation of [ 3 H]thymidine (PerkinElmer Life Sciences) (42) .
Transfection of siRNA
To down-regulate SRC-1 we transfected Dharmacon smart pool siRNA specific for SRC-1 and Dharmacon noncoding control siRNA (Dharmacon, Lafayette, CO) using AMAXA electroporation system (Amaxa, Gaithersburg, MD). To down-regulate ERK1 and ERK2 we used MAPK3 and MAPK1 smart pools (Dharmacon) and noncoding control siRNA. Two million LNCaP cells were electroporated with 1 nmol of siRNA according to the manufacturer's protocol, cells were then split into six wells of a six-well plate, treated, and used for RNA and protein analysis.
Chromatin Immunoprecipitation (ChIP) Assay
Cells plated at 2 million cells per 100-mm dish and maintained in medium supplemented with 10% charcoal stripped serum (sFBS) for 36 h were treated for a total of 16 h with vehicle or 20 M UO126; for the 16-h R1881 time point, 1 nM R1881 was added with U0126. For the 1-h R1881 treatment, R1881 was added for the last hour of U0126 treatment. The ChIP assay was performed as described previously (28) except that 1 g of N20 AR antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or antiacetyl-Histone H3 (Millipore) was used. The following TaqMan primer and probe sets were used to detect AR binding. The locations of the PSA enhancer and promoter have been described previously (43, 44) as have the TMPRSS2 enhancer and promoter (34) . The 
Real-Time Quantitative PCR and RT-PCR
Total RNA was prepared using TRIzol reagent (Invitrogen). Target genes were detected using TaqMan primer and probe sets (Applied Biosystems, Foster City, CA) using TaqMan One-Step RT-PCR master mix reagents (Applied Biosystems). The PCR was run on an ABI PRISM 7700 sequence detection system (Applied Biosystems). All data were normalized to the expression of 18S RNA. AR, PSA, PMEPA, and TMPRSS2 amplicons have been described previously (28) . PCDH-11 primers and probe were: TTGTTGTCCGGGACG-TACATTT, FAM-CGCGGTCCTGCTAGTATGCGTGGTG-TAMRA, TGGGCGCCAGAGTGGA.
Generation of Phosphorylation-Specific SRC-1 Antibodies
Antibodies were raised in rabbits and affinity purified by Bethyl Laboratories (Montgomery, TX). Antibody specificity was con-firmed as previously described for SRC-3 antibodies (31) (see supplemental Fig. 1 and figure legend , published as supplemental data on The Endocrine Society's Journals Online web site at http://mend.endojournals.org, for specificity). The peptide sequence used to generate the P-Thr 1179 antibody was (C)PPNYGTNPGT(PO 4 )PP and (C)GTPPASTS(PO 4 )PFSQLAA for Ser 1185 .
Immunoprecipitation
Ten COS-1 cell plates were plated at 10 6 cells per 100-mm plate and transfected with 2 g of flag-SRC1 expression plasmid. SRC-1 was expressed for 24 h, after which cells were treated with either DMSO or 20 M UO126 for 12 h. Cells were harvested in TEN buffer with protease and phosphatase inhibitors, lysed in FEB (50 mM Tris, pH 8; 5 mM EDTA, 1% Nonidet P-40, 0.2% sarkosyl, 0.4 M NaCl, 0.2 mM Na 3 VO 4 , 10 mM NaMoO 4 , 20 mM NaFl, 1 mM phenylmethylsulfonylfluoride), freeze thawed three times and cellular lysates spun for 5 min at 14,000 rpm at 4 C. Lysates were diluted 2-fold with TE (10 mM Tris, pH 8; 1 mM EDTA), incubated on ice for 10 min, and spun for 10 min at 100,000 rpm at 4 C. Clarified lysates were incubated with or without 5 g of anti-FLAG, 12.5 g rabbit antimouse antibody, and 75 l of 1:1 TE-protein A sepharose suspension for 1 h at 4 C. Cells were washed twice with 1:1 mix of TE and FEB, once with TE, and extracted twice with Laemmli buffer at 100 C. Eluates were resolved by SDS-PAGE and analyzed for total SRC-1 and phospho-SRC-1 levels by Western blotting.
Western Blotting
AR (using AR441 antibody), PSA (DakoCytomation, Glostrup, Denmark), Flag (Sigma), and SRC-1 (BD Pharmigen, San Diego, CA) Western blottings were performed exactly as we previously reported (4, 15) . SRC-1 phospho-Thr1179, and phospho-Ser1185 were detected using antibody produced by Bethyl Laboratories. Briefly, the membrane was blocked in 5% milk in TBST (10 mM Tris HCl plus 150 mM NaCl plus 0.1% Tween 20; pH 7.5) supplemented with phosphatase inhibitors (0.2 mM Na 3 VO 4 , 20 mM NaF) for 1 h at room temperature, incubated with primary antibody in 1% milk in TBST with phosphatase inhibitors overnight at 4 C, and incubated with rabbit antimouse horseradish peroxidase-conjugated antibody in TBST for 1 h at 4 C. Cyclin A2 and cyclin B were detected using 20 g of protein extract, resolved on 10% SDS-PAGE, and transferred to nitrocellulose membrane. The membrane was blocked in 1% milk solution in TBST, incubated with cyclin A2 antibody (Santa Cruz Biotechnology) diluted 1:400 or cyclin B antibody (BD Pharmigen) diluted 1:1000. Blots were washed three times in TBST and incubated with secondary antibody conjugated with horseradish peroxidase (GE Healthcare, Buckinghamshire, UK), and protein levels were analyzed using enhanced chemiluminescence detection reagent (Amersham Pharmacia Biotech, Piscataway, NJ).
Fluorescence-Activated Cell Sorting Analysis
C4-2 and LNCaP cells were harvested and fixed exactly as described previously (46) . Cells were sorted until 10 4 events accumulated. The percentage of cells in each cell phase was calculated, triplicates were averaged, and SE was calculated.
